Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Kite’s Yescarta Is First CAR-T To Move Into Second-Line Lymphoma

Executive Summary

Kite beats BMS’s Breyanzi to the first CAR-T approval in second-line large B-cell lymphoma. The added indication could nearly double the number of potential US patients for Yescarta.

You may also be interested in...



Precision’s Allo CAR-T Inches Closer To Filling Post-Auto CAR-T Niche

The company provided Phase I/IIa data for allogeneic CAR-T PBCAR0191 showing a high response rate and signs of durability in aggressive NHL patients relapsing after autologous CAR-T.

As CAR-T Therapies Move Into Earlier Lines, Best Uses Begin To Come Into Focus

Cost, logistics and safety could limit use of CAR-T therapies in first- and second-line treatment of hematologic malignancies, but for some patients there are clear benefits over standards of care.

Magrolimab Falls Off The Fast Track As Gilead Reveals New Clinical Holds

The company said in its fourth quarter earnings report that it would not seek accelerated approval for the drug, while it also settled an HIV drug-related intellectual property lawsuit with GSK/ViiV.

Related Content

Topics

Related Companies

Latest News
UsernamePublicRestriction

Register

SC146177

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel